Literature DB >> 34662187

The Role of mprF Mutations in Seesaw Effect of Daptomycin-Resistant Methicillin-Resistant Staphylococcus aureus Isolates.

Shengnan Jiang1,2, Hemu Zhuang1,2, Feiteng Zhu1,2, Xiang Wei2,3, Junxiong Zhang1,4, Lu Sun1,2, Shujuan Ji1,2, Haiping Wang1,2, Dandan Wu5, Feng Zhao6, Rushuang Yan1,2, Yunsong Yu1,2, Yan Chen1,2.   

Abstract

The emergence of daptomycin-resistant (DAP-R) Staphylococcus aureus strains has become a global problem. Point mutations in mprF are the main cause of daptomycin (DAP) treatment failure. However, the impact of these specific point mutations in methicillin-resistant S. aureus (MRSA) strains associated with DAP resistance and the "seesaw effect" of distinct beta-lactams remains unclear. In this study, we used three series of clinical MRSA strains with three distinct mutated mprF alleles from clone complexes (CC) 5 and 59 to explore the seesaw effect and the combined effect of DAP plus beta-lactams. Through construction of mprF deletion and complementation strains of SA268, we determined that mprF-S295A, mprF-S337L, and one novel mutation of mprF-I348del within the bifunctional domain lead to DAP resistance. Compared with wild-type mprF cloned from a DAP-susceptible (DAP-S) strain, these three mprF mutations conferred the seesaw effect to distinct beta-lactams in the SA268ΔmprF strains, and mutated mprF (I348del and S337L) did not alter the cell surface positive charge (P > 0.05). The susceptibility to beta-lactams increased significantly in DAP-R CC59 strains, and the seesaw effect was found to be associated with distinct mutated mprF alleles and the category of beta-lactams. The synergistic activity of DAP plus oxacillin was detected in all DAP-R MRSA strains. Continued progress in understanding the mechanism of restoring susceptibility to beta-lactam antibiotics mediated by the mprF mutation and its impact on beta-lactam combination therapy will provide fundamental insights into treatment of MRSA infections.

Entities:  

Keywords:  MRSA; beta-lactams; daptomycin; methicillin-resistant Staphylococcus aureus; mprF; seesaw effect; treatment

Mesh:

Substances:

Year:  2021        PMID: 34662187      PMCID: PMC8765318          DOI: 10.1128/AAC.01295-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.938


  40 in total

1.  Prolonged Exposure to β-Lactam Antibiotics Reestablishes Susceptibility of Daptomycin-Nonsusceptible Staphylococcus aureus to Daptomycin.

Authors:  Rachel E Jenson; Sarah L Baines; Benjamin P Howden; Nagendra N Mishra; Sabrina Farah; Cassandra Lew; Andrew D Berti; Sanjay K Shukla; Arnold S Bayer; Warren E Rose
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

Review 2.  Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies.

Authors:  Judith N Steenbergen; John F Mohr; Grace M Thorne
Journal:  J Antimicrob Chemother       Date:  2009-10-12       Impact factor: 5.790

3.  Successful treatment with daptomycin and ceftaroline of MDR Staphylococcus aureus native valve endocarditis: a case report.

Authors:  François-Régis Duss; Cristina Garcia de la Mària; Antony Croxatto; Stefano Giulieri; Frédéric Lamoth; Oriol Manuel; José M Miró
Journal:  J Antimicrob Chemother       Date:  2019-09-01       Impact factor: 5.790

4.  Combination Therapy for Methicillin-resistant Staphylococcus aureus (MRSA) Bacteremia: Beauty Remains in the Eye of the Beholder.

Authors:  Adolf W Karchmer
Journal:  Clin Infect Dis       Date:  2021-05-04       Impact factor: 9.079

Review 5.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

6.  Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.

Authors:  Brian J Werth; George Sakoulas; Warren E Rose; Joseph Pogliano; Ryan Tewhey; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2012-10-15       Impact factor: 5.191

7.  2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM).

Authors:  Gilbert Habib; Patrizio Lancellotti; Manuel J Antunes; Maria Grazia Bongiorni; Jean-Paul Casalta; Francesco Del Zotti; Raluca Dulgheru; Gebrine El Khoury; Paola Anna Erba; Bernard Iung; Jose M Miro; Barbara J Mulder; Edyta Plonska-Gosciniak; Susanna Price; Jolien Roos-Hesselink; Ulrika Snygg-Martin; Franck Thuny; Pilar Tornos Mas; Isidre Vilacosta; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

8.  In-Host Evolution of Daptomycin Resistance and Heteroresistance in Methicillin-Resistant Staphylococcus aureus Strains From Three Endocarditis Patients.

Authors:  Shujuan Ji; Shengnan Jiang; Xiang Wei; Lu Sun; Haiping Wang; Feng Zhao; Yan Chen; Yunsong Yu
Journal:  J Infect Dis       Date:  2020-03-16       Impact factor: 5.226

9.  Analysis of the Staphylococcus epidermidis genes epiF, -E, and -G involved in epidermin immunity.

Authors:  A Peschel; F Götz
Journal:  J Bacteriol       Date:  1996-01       Impact factor: 3.490

10.  Persistent Staphylococcus aureus isolates from two independent cases of bacteremia display increased bacterial fitness and novel immune evasion phenotypes.

Authors:  R L Richards; R D Haigh; B Pascoe; S K Sheppard; F Price; D Jenkins; K Rajakumar; J A Morrissey
Journal:  Infect Immun       Date:  2015-06-08       Impact factor: 3.441

View more
  1 in total

1.  Antibacterial activity of novel linear polyamines against Staphylococcus aureus.

Authors:  Edward J A Douglas; Abdulaziz H Alkhzem; Toska Wonfor; Shuxian Li; Timothy J Woodman; Ian S Blagbrough; Maisem Laabei
Journal:  Front Microbiol       Date:  2022-08-22       Impact factor: 6.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.